73 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
25 Apr 24
Report of Foreign Private Issuer
4:00pm
, easier routes of administration Lower immunogenicity Fewer contraindications Potentially safer & lower dose R&D Product Patient Safety & Convenience … and commercialization.
CLICK TO EDIT MASTER TITLE STYLE 38 BOUTIQUE CDMO SERVICES De - risking Scinai’s internal R&D investments by leveraging
F-3
SCNI
Scinai Immunotherapeutics Ltd
30 Jan 24
Shelf registration (foreign)
4:19pm
shareholders. The new strategy includes operating with two business units: an R&D business unit, and a Contract Development and Manufacturing Organization … (CDMO) business unit. The R&D business unit is focused on the development of NanoAbs licensed from the Max Planck Society (MPG) and the University
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
18 Jan 24
Report of Foreign Private Issuer
11:50am
safer & lower dose R&D Product Patient Safety & Convenience PLATFORM VALUE PROPOSITION
CLICK TO EDIT MASTER TITLE STYLE 8 Source of Risk Molecular Target … Wet AMD Drug Discovery (Max Planck) Est. – Estimated timing
CLICK TO EDIT MASTER TITLE STYLE 13 R&D STRATEGIC GUIDING PRINCIPLES Inflammation
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
9 Jan 24
Report of Foreign Private Issuer
8:45am
safer & lower dose R&D Product Patient Safety & Convenience PLATFORM VALUE PROPOSITION
CLICK TO EDIT MASTER TITLE STYLE 8 Source of Risk Molecular Target … Discovery (Max Planck) Est. – Estimated timing
CLICK TO EDIT MASTER TITLE STYLE 13 R&D STRATEGIC GUIDING PRINCIPLES Inflammation and Immunology
424B3
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Prospectus supplement
8:24am
that would generate the most favorable value for its shareholders. The new strategy includes operating with two business units: an R&D business unit … , and a Contract Development and Manufacturing Organization (CDMO) business unit. The R&D business unit is focused on the development of NanoAbs licensed from
F-1/A
2q1ppj
22 Dec 23
Registration statement (foreign) (amended)
9:11am
6-K
EX-99.2
pjvx 8wuudaxi6jir1a
14 Dec 23
Report of Foreign Private Issuer
6:21am
6-K
EX-99.1
nu82ovwlxdn2bo2z6rn
14 Dec 23
Report of Foreign Private Issuer
6:21am
6-K
EX-99.1
087t7
7 Nov 23
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
6:09am
6-K
EX-99.1
l5ntch8fb0
2 Nov 23
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
1:21pm
F-1
lyq86vjoemrjjjp 5guo
30 Oct 23
Registration statement (foreign)
4:59pm
6-K
EX-99.1
wj16w
6 Sep 23
Report of Foreign Private Issuer
12:01pm
6-K
EX-99.1
jifyp0izs9o ifwb7
23 Aug 23
Report of Foreign Private Issuer
6:10am
6-K/A
EX-99.1
93f1k
18 Aug 23
Current report (foreign) (amended)
10:07am
6-K/A
EX-99.2
w7j0vc
14 Aug 23
BiondVax Reports Second Quarter Financial Results and Provides Business Update
6:08am
6-K/A
EX-99.1
dk7l8
14 Aug 23
BiondVax Reports Second Quarter Financial Results and Provides Business Update
6:08am
6-K
EX-99.1
gkp1dwp
11 Aug 23
BiondVax Reports Second Quarter Financial Results and Provides Business Update
9:44am
6-K
EX-99.1
2007z
5 Jul 23
Report of Foreign Private Issuer
9:28am
10-Q
1m3rpy u2olyygc
15 May 23
Quarterly report
4:49pm
8-K
EX-99.1
uttzeue73r8pa85g
4 May 23
Regulation FD Disclosure
9:25am